Impact of hydroxychloroquine used as DMARD on SARS-CoV-2 tests and infection evolution in a population of 871 patients with inflammatory rheumatic and musculoskeletal diseases.
作者信息
Trefond Ludovic, Drumez Elodie, Andre Marc, Costedoat-Chalumeau Nathalie, Seror Raphaèle, Devaux Mathilde, Dernis Emmanuelle, Dieudonné Yannick, El Mahou Soumaya, Lanteri Aurelia, Melki Isabelle, Queyrel Viviane, Roumier Mathilde, Schmidt Jean, Barnetche Thomas, Thomas Thierry, Cacoub Patrice, Belot Alexandre, Aumaitre Olivier, Richez Christophe, Hachulla Eric
机构信息
Université Clermont Auvergne, CHU Clermont-Ferrand, Service de Médecine Interne, Hôpital Gabriel Montpied, Inserm U1071, INRA USC2018, M2iSH, 63000 Clermont-Ferrand, France.
Université de Lille, CHU Lille, ULR 2694-METRICS: Évaluation des technologies de santé et des pratiques médicales, 59000 Lille, France.
出版信息
Joint Bone Spine. 2021 Dec;88(6):105226. doi: 10.1016/j.jbspin.2021.105226. Epub 2021 May 26.
Abstract
摘要
相似文献
1
Impact of hydroxychloroquine used as DMARD on SARS-CoV-2 tests and infection evolution in a population of 871 patients with inflammatory rheumatic and musculoskeletal diseases.871例炎性风湿性和肌肉骨骼疾病患者中，使用羟氯喹作为改善病情抗风湿药对新冠病毒检测及感染进展的影响
Joint Bone Spine. 2021 Dec;88(6):105226. doi: 10.1016/j.jbspin.2021.105226. Epub 2021 May 26.
2
[SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease].[一名接受羟氯喹和抗TNFα治疗的炎性风湿性疾病患者感染了新型冠状病毒]
Pan Afr Med J. 2020 Aug 5;35(Suppl 2):134. doi: 10.11604/pamj.supp.2020.35.134.25011. eCollection 2020.
3
Acute generalized exanthematous pustulosis induced by hydroxychloroquine prescribed for COVID-19.用于治疗新冠肺炎的羟氯喹引发的急性泛发性脓疱性皮病
J Allergy Clin Immunol Pract. 2020 Sep;8(8):2777-2779.e1. doi: 10.1016/j.jaip.2020.05.046. Epub 2020 Jun 7.
4
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations.风湿肌肉骨骼疾病的免疫抑制剂治疗不会抑制对 SARS-CoV-2 感染的体液反应，并保留效应免疫细胞群体。
Front Immunol. 2022 Jun 10;13:873195. doi: 10.3389/fimmu.2022.873195. eCollection 2022.
5
How to manage rheumatic patients during the coronavirus pandemic.如何在新冠疫情期间管理风湿病患者。
Panminerva Med. 2020 Sep;62(3):176-177. doi: 10.23736/S0031-0808.20.03935-X. Epub 2020 Apr 28.
6
Hydroxychloroquine hitting the headlines-retinal considerations.羟氯喹登上新闻头条——视网膜相关考量
Eye (Lond). 2020 Jul;34(7):1158-1160. doi: 10.1038/s41433-020-0934-9. Epub 2020 May 19.
7
Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective.氯喹和羟氯喹——从风湿病学家的角度看潜在 COVID-19 药物的安全性概况。
Ann Agric Environ Med. 2021 Mar 18;28(1):122-126. doi: 10.26444/aaem/127766. Epub 2020 Oct 8.
8
Facts, not Fear: Safety of Hydroxychloroquine.事实，而非恐惧：羟氯喹的安全性
Am J Med Sci. 2020 Aug;360(2):199-200. doi: 10.1016/j.amjms.2020.05.003. Epub 2020 May 11.
9
Challenges and cares to promote rational use of chloroquine and hydroxychloroquine in the management of coronavirus disease 2019 (COVID-19) pandemic: a timely review.促进合理使用氯喹和羟氯喹治疗 2019 冠状病毒病（COVID-19）大流行的挑战与关切：及时综述。
J Toxicol Environ Health B Crit Rev. 2020 May 18;23(4):177-181. doi: 10.1080/10937404.2020.1752340. Epub 2020 Apr 12.
10
Regulatory Action to Protect Access to Hydroxychloroquine for Approved Rheumatic Indications During COVID-19 in New Zealand.新西兰在2019年冠状病毒病疫情期间采取的监管行动，以保护批准的风湿性适应症患者获得羟氯喹的机会。
Arthritis Rheumatol. 2021 May;73(5):896-897. doi: 10.1002/art.41643. Epub 2021 Mar 7.
引用本文的文献
1
Development of a Prediction Model for COVID-19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry.风湿性疾病患者新型冠状病毒肺炎急性呼吸窘迫综合征预测模型的开发：全球风湿病联盟注册研究结果
ACR Open Rheumatol. 2022 Oct;4(10):872-882. doi: 10.1002/acr2.11481. Epub 2022 Jul 22.
2
Effect of chronic hydroxychloroquine use on COVID-19 risk in patients with rheumatoid arthritis and systemic lupus erythematosus: a multicenter retrospective cohort.羟氯喹治疗类风湿关节炎和系统性红斑狼疮患者对 COVID-19 发病风险的影响：一项多中心回顾性队列研究。
J Int Med Res. 2022 Apr;50(4):3000605221090363. doi: 10.1177/03000605221090363.
3
Immunopathological events surrounding IL-6 and IFN-α: A bridge for anti-lupus erythematosus drugs used to treat COVID-19.围绕白细胞介素 6（IL-6）和干扰素-α（IFN-α）的免疫病理事件：治疗 COVID-19 时用于治疗红斑狼疮的药物的桥梁。
Int Immunopharmacol. 2021 Dec;101(Pt B):108254. doi: 10.1016/j.intimp.2021.108254. Epub 2021 Oct 14.
Zotero 插件